Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics. 2011;21:237–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee AM, Shi Q, Pavey E, Alberts SR, Sargent DJ, Sinicrope FA, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106:dju298.

Article  PubMed  PubMed Central  Google Scholar 

World Health Organisation (WHO). The selection of essential drugs (1977) - TRS 615. (1977) https://www.who.int/publications/i/item/9241206152. Accessed 20th November 2023.

World Health Organisation (WHO). The selection and use of essential medicines (2015) - TRS 994. (2015) https://www.who.int/publications/i/item/9789241209946. Accessed 20th November 2023.

European Medicines Agency (EMA). Referral under Article 31 of Directive 2001/83/EC resulting from pharmacovigilance data: fluorouracil and fluorouracil-related substances (capecitabine, tegafur and flucytosine) containing medicinal products. (2020) https://www.ema.europa.eu/en/documents/referral/fluorouracil-fluorouracil-related-substances-article-31-referral-assessment-report_en.pdf. Accessed 20th November 2023.

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 Update. Clin Pharm Ther. 2018;103:210–6.

Article  CAS  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

Article  PubMed  Google Scholar 

Meta-Analysis Group In C, Levy E, Piedbois P, Buyse M, Pignon JP, Rougier P, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol. 1998;16:3537–41.

Article  Google Scholar 

Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiader CR. Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. Int J Cancer. 2015;136:730–9.

Article  CAS  PubMed  Google Scholar 

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:1639–50.

Article  CAS  PubMed  Google Scholar 

Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl J Med. 2000;343:905–14.

Article  CAS  PubMed  Google Scholar 

Bajetta E, Procopio G, Celio L, Gattinoni L, Della Torre S, Mariani L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23:2155–61.

Article  CAS  PubMed  Google Scholar 

Tsalic M, Bar-Sela G, Beny A, Visel B, Haim N. Severe toxicity related to the 5-fluorouracil/leucovorin combination (the Mayo Clinic regimen): a prospective study in colorectal cancer patients. Am J Clin Oncol. 2003;26:103–6.

Article  CAS  PubMed  Google Scholar 

Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–92.

Article  CAS  PubMed  Google Scholar 

van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19:4097–106.

Article  PubMed  Google Scholar 

Tuchman M, Stoeckeler JS, Kiang DT, O’Dea RF, Ramnaraine ML, Mirkin BL. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. N. Engl J Med. 1985;313:245–9.

Article  CAS  PubMed  Google Scholar 

Sommadossi JP, Gewirtz DA, Diasio RB, Aubert C, Cano JP, Goldman ID. Rapid catabolism of 5-Fluorouracil in freshly isolated rat hepatocytes as analyzed by high-performance liquid-chromatography. J Biol Chem. 1982;257:8171–6.

Article  CAS  PubMed  Google Scholar 

Traut TW, Loechel S. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay. Biochemistry. 1984;23:2533–9.

Article  CAS  PubMed  Google Scholar 

Diasio RB, Beavers TL, Carpenter JT. Familial deficiency of dihydropyrimidine dehydrogenase. biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest. 1988;81:47–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer. 1991;68:499–501.

Article  CAS  PubMed  Google Scholar 

Takimoto CH, Lu ZH, Zhang R, Liang MD, Larson LV, Cantilena LR Jr., et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.

CAS  PubMed  Google Scholar 

van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer. 2004;40:939–50.

Article  PubMed  Google Scholar 

Lunenburg C, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, et al. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet. 2020;28:508–17.

Article  CAS  PubMed  Google Scholar 

Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther. 2006;5:2895–904.

Article  CAS  PubMed  Google Scholar 

van Kuilenburg AB, van Lenthe H, van Gennip AH. Activity of pyrimidine degradation enzymes in normal tissues. Nucleosides Nucleotides Nucleic Acids. 2006;25:1211–4.

Article  PubMed  Google Scholar 

van Kuilenburg AB, van Lenthe H, Blom MJ, Mul EP, van Gennip AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer. 1999;79:620–6.

Article  PubMed  PubMed Central  Google Scholar 

Johnson MR, Wang K, Tillmanns S, Albin N, Diasio RB. Structural organization of the human dihydropyrimidine dehydrogenase gene. Cancer Res. 1997;57:1660–3.

CAS  PubMed  Google Scholar 

Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998;51:391–400.

Article  CAS  PubMed  Google Scholar 

Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Henricks LM, Lunenburg C, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19:1459–67.

Article  CAS  PubMed  Google Scholar 

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34:227–34.

Article  CAS  PubMed